Investigational drug · Phase 3
Danicamtiv
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Symptomatic Genetic Dilated Cardiomyopathy (DCM), Symptomatic Genetic Dilated Cardiomyopathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "Danicamtiv"
First trial start
2026
Feb 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Danicamtiv", any sponsor or status.
Conditions studied
As listed on its trial records.
- Symptomatic Genetic Dilated Cardiomyopathy (DCM)
- Symptomatic Genetic Dilated Cardiomyopathy
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Danicamtiv" as an intervention, largest first.
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated CardiomyopathyPivotal-lookingRecruiting
Kardigan, Inc.Industry
NCT07771465 · 332 participants (planned) · Start Aug 26, 2026 · Primary completion Nov 2032
Drug: Danicamtiv · For: Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 78 sites in all
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyPivotal-lookingRecruiting
Kardigan, Inc.Industry
NCT07210723 · 332 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 2027
Drug: danicamtiv; Placebo · For: Symptomatic Genetic Dilated Cardiomyopathy
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 79 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04572893 · 41 participants · Start Aug 4, 2020 · Primary completion Feb 22, 2024
Drug: danicamtiv · For: Primary Familial Dilated Cardiomyopathy
Sites: La Jolla, California; Washington D.C., District of Columbia; Tampa, Florida · 19 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05806359 · 33 participants · Start Mar 31, 2023 · Primary completion Aug 14, 2023
Drug: Danicamtiv; Placebo · For: Healthy Volunteers
Sites: Anaheim, California
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05162222 · 30 participants · Start Dec 15, 2021 · Primary completion Jul 8, 2022
Drug: Danicamtiv; Itraconazole and 1 more · For: Healthy Participants
Sites: Dallas, Texas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06027437 · 21 participants · Start Sep 5, 2023 · Primary completion Nov 10, 2023
Drug: Danicamtiv · For: Healthy Volunteers
Sites: Anaheim, California
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05952089 · 13 participants · Start Aug 17, 2023 · Primary completion Mar 15, 2024
Drug: Danicamtiv; Midazolam · For: Heart Failure With Reduced Ejection Fraction
Sites: Fort Lauderdale, Florida; Inverness, Florida; Jacksonville, Florida · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The role of cardiac myosin activators in dilated cardiomyopathy pharmacotherapy.
Salas Garcia E, Taylor MRG, Mestroni L, et al. · Expert Opin Pharmacother 2026
- Cardiac Myosin Activators in Heart Failure: Experimental Advances Amid Clinical Uncertainty.
Hou L, Lin B, Ji X, et al. · Drug Des Devel Ther 2026
- Efficacy of cardiac myosin activators compared to placebo in patients with heart failure and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials.
Samaniego-Laguna MA, Tripoli A, Gamarra-Valverde NN, et al. · Heart Lung 2026
- Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial.
Lakdawala NK, Hershberger RE, Garcia-Pavia P, et al. · J Am Coll Cardiol 2025
- Danicamtiv increases cardiac mechanical efficiency.
Meehan T, Pham T, Tran K, et al. · J Physiol 2025
- Danicamtiv reduces myosin's working stroke but activates the thin filament by accelerating actomyosin attachment.
Scott B, Greenberg L, Squarci C, et al. · Proc Natl Acad Sci U S A 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.